동반진단(CDx) : 기술과 시장

Highlights:

The global market for companion diagnostics (CDx) is estimated to increase from $6.4 billion in 2022 to reach $13.0 billion by 2027, at a compound annual growth rate (CAGR) of 15.3% from 2022 through 2027.

The global market for companion diagnostics consumables is estimated to increase from $3.6 billion in 2022 to reach $7.5 billion by 2027, at a CAGR of 15.8% from 2022 through 2027.

The global market for companion diagnostics services is estimated to increase from $1.3 billion in 2022 to reach $2.7 billion by 2027, at a CAGR of 15.6% from 2022 through 2027.

Report Scope:

The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints and challenges in the market. The report also features market projections to 2027 and market ranking for key market players. It also covers the competitive environment and regulatory scenario. The report details the companion diagnostics market share based on product and Service, type of test, technology and application. The market is segmented based on product and Service into instruments, consumables and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, others, and services. Based on the application, the companion diagnostics market is segmented into cancer, neurologic disorders, cardiovascular disease, infectious disease and others. The report includes company profiles of the key players in the companion diagnostics market with detailed information about each company's business segments, financials, product portfolios and recent developments. The report also covers the impact of the COVID-19 pandemic on this market.

By geography, the market has been segregated into North America, Europe, Asia-Pacific and the Rest of the world. The North American region includes countries such as the U.S. and Canada; Europe includes Germany, U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 as the historic year, 2021 as the base year and 2027 as the forecast year.

Report Includes:

• 43 data tables and 60 additional tables
• Detailed overview and an up-to-date analysis of the global market for companion diagnostics (CDx)
• Analyses of the global market trends, with historic market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
• Estimation of the actual market size and revenue forecast for the global CDx market in USD million values, and corresponding market share analysis by product and service, technology, application, type of test, and region
• Identification of the viable technology drivers and barriers through a holistic review of various platform technologies and their potential applications in the development of new CDx products
• Discussion of feasible market opportunities for companion diagnostics products via identification of high-growth applications in different therapeutic areas, with a focus on the biggest and fastest-expanding markets for diseases
• Updated information on recent market developments and clinical trials, as well as the leading companies engaged in research and development (R&D) and products in the companion diagnostics reagent pipeline with SWOT analyses
• Review of the patents and patent applications on companion diagnostics and deep dive of recent patent publications related to CDx products and technologies
• Insight into the recent industry structure of companion diagnostics, competitive aspects of each product segments, increasing investment on R&D activities, market growth strategies, and company revenue share analysis
• Descriptive company profiles of the leading global players, including Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Foundation Medicine Inc., Myriad Genetics Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction

• 1.1 Overview
• 1.2 Study Goals and Objectives
• 1.3 Reasons for Doing This Study
• 1.4 What's New in This Update?
• 1.5 Scope of Report
• 1.6 Information Sources
• 1.7 Research Methodology
• 1.8 Geographic Breakdown
• 1.9 Analyst's Credentials
• 1.10 BCC Custom Research
• 1.11 Related BCC Research Reports

Chapter 2 Summary and Highlights

• 2.1 Highlights of the Market for Companion Diagnostics (CDx)

Chapter 3 Market and Technology Background

• 3.1 Introduction
• 3.2 Personalized Medicine and Biomarkers
  • 3.2.1 Predictive Biomarkers
• 3.3 Companion Diagnostics and Complementary Diagnostics
  • 3.3.1 Companion Diagnostics Development
  • 3.3.2 CDx Stakeholders
  • 3.3.3 Technologies Used in CDx
  • 3.3.4 Applications of CDx
  • 3.3.5 Regulatory Aspects of CDx

Chapter 4 Global Market for Companion Diagnostics by Product and Service

• 4.1 Market Overview
• 4.2 Market Share and Forecast
  • 4.2.1 Instruments
  • 4.2.2 Consumables
  • 4.2.3 Services

Chapter 5 Global Market for Companion Diagnostics by Type of Test

• 5.1 Market Overview
• 5.2 Market Share and Forecast
  • 5.2.1 LDT-CDx
  • 5.2.2 Commercial CDx

Chapter 6 Global Market for Companion Diagnostics by Technology

• 6.1 Market Overview
• 6.2 Market Share and Forecast
  • 6.2.1 Immunohistochemistry
  • 6.2.2 In Situ Hybridization
  • 6.2.3 Polymerase Chain Reaction
  • 6.2.4 Next-Generation Sequencing
  • 6.2.5 Genotyping
  • 6.2.6 Others
  • 6.2.7 Services

Chapter 7 Global Market for Companion Diagnostics by Application

• 7.1 Market Overview
• 7.2 Market Share and Forecast
  • 7.2.1 Cancer
  • 7.2.2 Market for the Application of CDx in Cancer by Type
  • 7.2.3 Neurologic Disorders
  • 7.2.4 Cardiovascular Disease
  • 7.2.5 Infectious Disease
  • 7.2.6 Other Diseases

Chapter 8 Global Market for Companion Diagnostics by Region

• 8.1 North America
  • 8.1.1 U.S.
  • 8.1.2 Canada
• 8.2 Europe
  • 8.2.1 Germany
  • 8.2.2 U.K.
  • 8.2.3 France
  • 8.2.4 Italy
  • 8.2.5 Rest of Europe
• 8.3 Asia-Pacific
  • 8.3.1 China
  • 8.3.2 Japan
  • 8.3.3 India
  • 8.3.4 Rest of Asia-Pacific
• 8.4 Rest of the World

Chapter 9 Industry Structure

• 9.1 Overview
• 9.2 Stakeholders in Companion Diagnostics
• 9.3 Driving Trends in Companion Diagnostics
• 9.4 Business Models of Companion Diagnostics
• 9.5 Grants and Funding in Companion Diagnostics
• 9.6 Collaborations and Partnerships
• 9.7 Mergers and Acquisitions
  • 9.7.1 Market Share Analysis
• 9.8 Leading Market Players in Companion Diagnostics Market, by Technology
  • 9.8.1 Leading Market Players in IHC Market
  • 9.8.2 Leading Market Players in ISH Market
  • 9.8.3 Leading Market Players in PCR Market
  • 9.8.4 Leading Market Players in NGS Market
  • 9.8.5 Leading Market Players in Genotyping Market
  • 9.8.6 Leading Market Players in Others (Tropism, MRI) CDx Market

Chapter 10 Patent Review

• 10.1 Introduction
• 10.2 Patents on Companion Diagnostics Market
• 10.3 Patent Analysis
  • 10.3.1 Patents by Year
  • 10.3.2 Patents by Top Applicant
  • 10.3.3 Patents by Top Owner
  • 10.3.4 Patents by Jurisdiction

Chapter 11 Clinical Trials Analysis

• 11.1 Introduction
• 11.2 Clinical Trials and CDx
• 11.3 Clinical Trials Analysis
  • 11.3.1 Clinical Trials Analysis, by Type of Study
  • 11.3.2 Clinical Trials Analysis, by Status
  • 11.3.3 Clinical Trials Analysis, by Phase
  • 11.3.4 Clinical Trials Analysis, by Region
  • 11.3.5 Clinical Trials Analysis, by Application
  • 11.3.6 Companies with Companion Diagnostics in Clinical Trials

Chapter 12 Analysis of Market Opportunities

• 12.1 Introduction
• 12.2 Market Dynamics
  • 12.2.1 Strengths
  • 12.2.2 Challenges
  • 12.2.3 Opportunities
  • 12.2.4 Threats
• 12.3 Impact of the COVID-19 Pandemic

Chapter 13 Company Profiles

• ABBOTT
• ADAPTIVE BIOTECHNOLOGIES CORP.
• AGILENT TECHNOLOGIES INC.
• AMOY DIAGNOSTICS CO., LTD.
• ALMAC GROUP LTD.
• ARUP LABORATORIES
• AUTOGENOMICS INC. (ACQUIRED BY PRESCIENT MEDICINE)
• BIOCARTIS
• BIODESIX INC.
• BIOFLUIDICA
• BIOMERIEUX SA
• BIO-TECHNE
• CERBA RESEARCH
• CIRCULOGENE
• DANAHER
• DIASORIN S.P.A.
• EXACT SCIENCES CORP.
• F. HOFFMANN-LA ROCHE LTD.
• GUARDANT HEALTH INC.
• HOLOGIC INC.
• ICON PLC
• ILLUMINA INC.
• INVIVOSCRIBE INC.
• MAZE THERAPEUTICS
• MYRIAD GENETICS INC.
• NEOGENOMICS LABORATORIES
• QIAGEN
• QUEST DIAGNOSTICS INC.
• RESONANCE HEALTH LTD.
• SIEMENS HEALTHINEERS AG
• SPARTAN BIOSCIENCE INC.
• SYSMEX CORP.
• THERMO FISHER SCIENTIFIC INC.
• TRIMGEN CORP.
• VELA DIAGNOSTICS INC.

Chapter 14 Appendix: Acronyms